PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
Mikhail Kosiborod

Mikhail Kosiborod

Heart Failure & Transplant
Saint Luke's Health System

About

Mikhail Kosiborod works in Heart Failure & Transplant affiliated with Saint Luke's Health System.

Mikhail Kosiborod is a cardiologist serving as Senior Vice President of Late-Stage Development for Cardiovascular, Renal and Metabolism at AstraZeneca. He holds the position of Professor of Medicine at the University of Missouri-Kansas City and is affiliated with Saint Luke's Mid America Heart Institute. He also has research affiliations with The George Institute for Global Health at UNSW Sydney.

Research focus

SGLT2 Inhibitors in Heart FailureHeart Failure with Preserved Ejection FractionCardiometabolic SyndromesCardiorenal SyndromesDiabetes and Cardiovascular Disease Management

Impact

837 pubs · 60,048 cites · h-index 113

Training

  • MD

    Mount Sinai School of Medicine

    1997

  • Residency in Internal Medicine

    Yale University School of Medicine

  • Fellowship in Cardiovascular Medicine

    Yale University School of Medicine

    2005

Affiliations

Work Experience

Senior Vice President Late-Stage Development, CVRM

AstraZeneca · 2025 - Present

Vice President of Research

Saint Luke’s Health System · 2005 - Present

Director of Cardiometabolic Research

Saint Luke’s Mid America Heart Institute · 2005 - Present

Professor of Medicine

University of Missouri–Kansas City · 2005 - Present

Publications